Mental DailyMental Daily
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • The Discussion
    • My Bookmarks
Aa
Mental Daily
Aa
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • Opinion
Search
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • The Discussion
    • My Bookmarks
Follow US
  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store
© 2022 - Mental Daily. All Rights Reserved.
Clinical

Brisk walking may reduce the severity of symptoms associated with postpartum depression

Staff Writer
Staff Writer 7 months ago
Updated 2021/10/28 at 3:45 AM
Share
SHARE

A study in the Journal of Women’s Health suggests that brisk walking may reduce the severity of symptoms associated with postpartum depression.

Conducted by a team of Canadian researchers, data from five research projects were analyzed, which involved more than 200 participants.

In the study, researchers recommended walking at a moderate intensity for 90 to 120 minutes per week, or as little as 15 minutes per day.

“Rising demands for traditional postpartum depression (PPD) treatment options (e.g., psychiatry), especially in the context of the COVID-19 pandemic, are increasingly difficult to meet,” the authors stated in the journal article.

“More accessible treatment options (e.g., walking) are needed.”

“While limited by a relatively small number of included studies, pooled effect estimates suggest that walking may help mothers manage PPD. This is the first-time walking as treatment for PPD, an exercise modality that uniquely addresses many barriers faced by mothers, has been summarized in a systematic way,” according to researchers.

Photo: Adobe Stock

You Might Also Like

Type 2 diabetes may lead to a significant increase in brain aging and cognitive decline

Study finds no structural brain change during mindfulness-based stress training

Study finds diet may be a contributing factor in ADHD symptoms associated in children

New research claims COVID-19 contagion may raise the risk of neurodegenerative disorder

ALS experimental drug NU-9 more efficacious than existing FDA-approved drugs

TAGGED: mental health, postpartum depression
Staff Writer October 27, 2021
Share this Article
Facebook Twitter Whatsapp Whatsapp Email Print
Previous Article Study suggests green tea catechins EGCG and ECG may boost oxidative stress
Next Article New research entertains the theory of antidepressant efficacy as early-COVID-19 treatment

Recommended

Clinical

Type 2 diabetes may lead to a significant increase in brain aging and cognitive decline

1 Min Read
Clinical

Study finds no structural brain change during mindfulness-based stress training

1 Min Read
Clinical

Study finds diet may be a contributing factor in ADHD symptoms associated in children

1 Min Read
Clinical

New research claims COVID-19 contagion may raise the risk of neurodegenerative disorder

1 Min Read
//

We are a trusted online source for research news and resources on all aspects of the mind and human behavior.

Verticals

  • Clinical
  • Health
  • Social
  • I/O
  • Opinion

Social

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Links

  • About
  • Contact
  • Terms & Conditions
  • Privacy Policy
Follow US

© 2022 Mental Daily. All Rights Reserved.

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?